tiprankstipranks
Viatris Inc. Expands Board and Welcomes New Expert Director
PremiumCompany AnnouncementsViatris Inc. Expands Board and Welcomes New Expert Director
2M ago
Viatris lowers FY24 adjusted EPS view to $2.66-$2.81 from $2.70-$2.85
PremiumThe Fly
Viatris lowers FY24 adjusted EPS view to $2.66-$2.81 from $2.70-$2.85
2M ago
Viatris reports Q1 adjusted EPS 67c, consensus 67c
PremiumThe Fly
Viatris reports Q1 adjusted EPS 67c, consensus 67c
2M ago
Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
PremiumThe FlyOcuphire Pharma announces U.S. commercial launch of RYZUMVI
4M ago
Viatris announces U.S. commercial launch of Ryzumvi
PremiumThe Fly
Viatris announces U.S. commercial launch of Ryzumvi
4M ago
Viatris price target raised to $13 from $11 at Piper Sandler
PremiumThe Fly
Viatris price target raised to $13 from $11 at Piper Sandler
4M ago
Viatris reports Q4 EPS (64c), consensus 65c
PremiumThe FlyViatris reports Q4 EPS (64c), consensus 65c
5M ago
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
PremiumPress Releases
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
5M ago
Viatris, Idorsia enter agreements for global research and development
PremiumThe Fly
Viatris, Idorsia enter agreements for global research and development
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100